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Abstract
Multiple osteochondromas (MO) is characterised by development of two or more cartilage capped
bony outgrowths (osteochondromas) of the long bones. The prevalence is estimated at 1:50,000,
and it seems to be higher in males (male-to-female ratio 1.5:1). Osteochondromas develop and
increase in size in the first decade of life, ceasing to grow when the growth plates close at puberty.
They are pedunculated or sessile (broad base) and can vary widely in size. The number of
osteochondromas may vary significantly within and between families, the mean number of locations
is 15–18. The majority are asymptomatic and located in bones that develop from cartilage,
especially the long bones of the extremities, predominantly around the knee. The facial bones are
not affected. Osteochondromas may cause pain, functional problems and deformities, especially of
the forearm, that may be reason for surgical removal. The most important complication is
malignant transformation of osteochondroma towards secondary peripheral chondrosarcoma,
which is estimated to occur in 0.5–5%. MO is an autosomal dominant disorder and is genetically
heterogeneous. In almost 90% of MO patients germline mutations in the tumour suppressor genes
EXT1 or EXT2 are found. The EXT genes encode glycosyltransferases, catalyzing heparan sulphate
polymerization. The diagnosis is based on radiological and clinical documentation, supplemented
with, if available, histological evaluation of osteochondromas. If the exact mutation is known
antenatal diagnosis is technically possible. MO should be distinguished from metachondromatosis,
dysplasia epiphysealis hemimelica and Ollier disease. Osteochondromas are benign lesions and do
not affect life expectancy. Management includes removal of osteochondromas when they give
complaints. Removed osteochondromas should be examined for malignant transformation towards
secondary peripheral chondrosarcoma. Patients should be well instructed and regular follow-up for
early detection of malignancy seems justified. For secondary peripheral chondrosarcoma, en-bloc
resection of the lesion and its pseudocapsule with tumour-free margins, preferably in a bone
tumour referral centre, should be performed.
Disease name and synonyms
Multiple Osteochondromas (MO) MIM 133700
Hereditary Multiple Exostoses (HME), Multiple Heredi-
tary Exostoses (MHE), EXT, diaphyseal aclasis, (multiple
hereditary) osteochondromatosis, multiple cartilaginous
exostoses
Definition and diagnostic criteria
Osteochondroma (osteocartilaginous exostosis) is a carti-
lage capped bony projection arising on the external sur-
face of bone containing a marrow cavity that is
continuous with that of the underlying bone [1]. A diag-
nosis of MO can be made when radiologically at least two
osteochondromas of the juxta-epiphyseal region of long
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bones are observed. In the majority of patients a positive
family history and/or mutation in one of the EXT genes
can be detected [2,3].
Epidemiology
The prevalence of MO is estimated at 1:50,000 persons
within the general population [4] and seems to be higher
in males (male-to-female ratio 1.5:1) [2,5]. This is proba-
bly due to the fact that females tend to have a milder phe-
notype and are therefore more easily overlooked [2]. The
solitary (sporadic) form of osteochondroma is approxi-
mately six times more common than the occurrence
within the context of MO. Approximately 62% of the
patients with multiple osteochondromas have a positive
family history [2].
Clinical description
Osteochondromas develop and increase in size in the first
decade of life, ceasing to grow when the growth plates
close at puberty. They are pedunculated or sessile (broad
base) and can vary widely in size. The majority are asymp-
tomatic and located in bones that develop from cartilage,
especially the long bones of the extremities, predomi-
nantly around the knee (Figures 1 and 2A). The facial
bones are not affected. The number of osteochondromas
may vary significantly within and between families, the
mean number of locations is 15–18 [6]. In addition, in
MO patients a variety of orthopaedic deformities can be
found like deformities of the forearm (shortening of the
ulna with secondary bowing of radius) (39–60%) [4,6,7]
(Figure 2C), inequality in limb length (10–50%) [4,7],
varus or valgus angulation of the knee (8–33%) [4,7],
deformity of the ankle (2–54%) [4,7] and disproportion-
ate short stature (37–44%) [2,5,6].
Other complications of the osteochondromas include
osseous and cosmetic deformities, bursa formation,
arthritis (14%) [5] and impingement on adjacent ten-
dons, nerves (22.6%) [5], vessels (11.3%) [5] or spinal
cord (0.6%) [5,8]. MO patients may have abnormal scar
formation [9]. Osteochondromas bear the risk for fracture
of the bony stalk during physical exercise. This is esti-
mated to occur in approximately 5% of osteochondromas
[10] and may be reason for surgical removal.
Examples of radiographs demonstrating multiple osteochondromas around the knee (A) and at the pelvis and proximal femur  (B), while (C) demonstrates the deformity of the forearm (shortening of the ulna with secondary bowing of radius) that is  found in 39–60% of the patients. Figure 2
Examples of radiographs demonstrating multiple osteochondromas around the knee (A) and at the pelvis and proximal femur 
(B), while (C) demonstrates the deformity of the forearm (shortening of the ulna with secondary bowing of radius) that is 
found in 39–60% of the patients.
Photograph of the legs of a 26 year old male showing multi- ple lumps leading to deformity Figure 1
Photograph of the legs of a 26 year old male showing 
multiple lumps leading to deformity.Orphanet Journal of Rare Diseases 2008, 3:3 http://www.ojrd.com/content/3/1/3
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The majority of MO patients experiences pain [11,12],
approximately half of which concerns generalised pain
[11]. Therefore, the number of MO individuals having
pain has been underestimated and pain seems a problem
that must be addressed when caring for MO patients. The
occurrence of pain was associated with MO related com-
plications and surgery [11].
The most important complication of MO is malignant
transformation of an osteochondroma, which is esti-
mated to occur in 0.5–5% of patients [2,4,5,13,14]. Clin-
ical signs of malignant transformation include an increase
in size and pain [6]. Malignant transformation of osteo-
chondroma leads to a secondary peripheral chondrosar-
coma in 94% of the cases [15]. The suspicion of secondary
chondrosarcoma is indicated by growth of the tumour
after puberty, the presence of pain, or a thickness over 1
cm of the cartilaginous cap in adults.
Aetiology
Two genes, EXT1 and EXT2 located respectively at 8q24
and 11p11-p12, have been isolated to cause MO [16-19].
Additional linkage to chromosome 19p has been found,
suggesting the existence of an EXT3-gene [20]. However,
the gene has never been identified. Moreover, the
increased sensitivity of mutation detection and the use of
new techniques screening for larger deletions, such as
MLPA, have dramatically decreased the proportion of MO
patients without an EXT1 or EXT2 mutation to <15% [21-
23]. These data question the existence of an EXT3-gene at
19p.
The EXT1 gene is composed of 11 exons and has a coding
region of 2238 bp [17-24]. The EXT2-gene contains 16
exons [18,19] and its cDNA defines a single open reading
frame of 2154 bp. EXT1 and EXT2 are highly similar, espe-
cially in the carboxy terminal region [18,19].
The EXT1 gene was reported to show linkage in 44%–66%
of the MO families [25,26], whereas EXT2  would be
involved in 27% [26]. Germline mutations of EXT1 and
EXT2 in MO patients have been studied extensively in
Caucasian as well as Asian populations [27]. In EXT1,
mutations are more or less randomly distributed over the
first 6 exons, while the last 5 exons, containing the con-
served carboxyterminal region, contain significantly less
mutations [27]. Similarly, in EXT2 most mutations are
found in the first eight exons. No mutational hotspots are
found. Approximately 80% of the mutations are either
non-sense, frameshift, or splice-site mutations leading to
premature termination of EXT proteins [25,28-32]. The
majority of missense mutations also lead to defective EXT
protein function [33]. Mutations in EXT1 seem associated
with a more severe phenotype as compared to EXT2 [34-
37].
It has long been thought that osteochondromas are the
result of skeletal dysplasia. It is now however generally
accepted that osteochondromas are neoplastic, since
genetic changes are found in the cartilage cap [1,38-42].
The EXT-genes are tumour suppressor genes. Loss of the
remaining EXT1 wildtype allele has been demonstrated in
the cartilage cap of osteochondromas from MO patients
[39]. However, in a considerable proportion of MO
patients loss of the remaining wildtype allele could not be
detected so far [43]. In seven out of eight solitary osteo-
chondromas, homozygous deletions of EXT1 are found
[38] further supporting the two-hit model. Moreover, the
deletions were confined to the cartilage cap. Thus, the car-
tilage cap is the clonal neoplastic element, while the stalk
is reactive [38].
Both  EXT1  and  EXT2  mRNA is ubiquitously expressed
[17-19]. A high level of expression of Ext1 and Ext2 mRNA
has been found in developing limb buds of mouse
embryos [44,45] and expression was demonstrated to be
confined to the proliferating and prehypertrophic
chondrocytes of the growth plate [46]. In osteochondro-
mas and peripheral chondrosarcomas the expression of
EXT1  and/or  EXT2  is decreased, corresponding to the
mutation status [47].
The gene products, exostosin-1 (EXT1) and exostosin-2
(EXT2), are endoplasmic reticulum localized type II trans-
membrane glycoproteins which form a Golgi-localised
hetero-oligomeric complex that catalyzes heparan sul-
phate (HS) polymerization [48-51]. Heparan sulphate
proteoglycans (HSPG) are large macromolecules com-
posed of heparan sulphate glycosaminoglycan chains
linked to a protein core. Four important HSPG families
are syndecan, glypican, perlecan and isoforms of CD44
bearing variable exon 3 (CD44v3). In osteochondromas
in which EXT expression is decreased due to mutation or
deletion, the heparan sulphate proteoglycans seem to
accumulate in the cytoplasm of the cell, instead of being
transported to be expressed at the cell surface [47].
EXT and HSPGs are required for high-affinity binding of
fibroblast growth factor to its receptor and for the diffu-
sion of the morphogens Hedgehog (Hh, human homo-
logues Indian (IHH) and Sonic Hedgehog (SHH) [52-54],
decapentaplegic (dpp, human homologues TGF-beta and
BMP) and wingless (wng, human homologue Wnt)
[55,56]. These three pathways are important during devel-
opment and are specifically active in the growth plate dur-
ing endochondral bone formation. During normal
growth, IHh and PTHLH are involved in a delicate para-
crine feedback loop regulating proliferation and differen-
tiation of the chondrocytes of the growth plate (Figure 3).
In osteochondroma, IHH signalling is still active and is
probably cell autonomous [57,58]. PTHLH signalling,Orphanet Journal of Rare Diseases 2008, 3:3 http://www.ojrd.com/content/3/1/3
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which is downstream of IHH and is responsible for
chondrocyte proliferation, is absent in osteochondroma,
while being upregulated upon malignant transformation
of osteochondroma [59,60]. Wnt signalling and TGF-beta
signalling are also active in the majority of osteochondro-
mas [57]. The exact role of EXT in orchestrating these
pathways leading to osteochondroma formation in MO
patients needs to be further elucidated.
Diagnostic methods
When a patient is suspected to have MO, the full radiolog-
ical documentation, histology (if available), patient his-
tory and family history have to be carefully reviewed.
Given the specific radiological and histological expertise
needed, and the rarity of the disorder and of those in the
differential diagnosis, it is recommended that this review
is performed by specialists in the field, for instance
through a national bone tumour registry consisting of cli-
nicians, radiologists and pathologists. If this review is
indicative for MO, the peripheral blood of the patient may
be screened for germline mutations in EXT1 or EXT2 [61].
In case of a positive family history in which MO is clearly
established in relatives, the diagnosis of MO can be clini-
cally made and mutation analysis is not essential. With
the currently used methods it is possible to detect point
mutations or gross deletions in almost 90% of MO
patients [21-23,61-63].
To evaluate possible malignant transformation in case of
complaints or growth of the lesion after puberty, the size
of the cartilaginous cap can be well established with T2-
weighted magnetic resonance (MR) imaging [64]. A carti-
lage cap >1.5 cm should be regarded with caution. The
role of 18 Fluoro-deoxyglucose positron emission tomog-
raphy (18FDG PET) needs to be further established [65].
Differential diagnosis
Dysplasia Epiphysealis Hemimelica (DEH, Trevor's dis-
ease, tarso-epiphysial aclasis) and metachondromatosis
(MC) are considered in the differential diagnosis of soli-
tary and hereditary osteochondromas. Despite their simi-
larities, they were shown to be separate entities [66] and
the EXT downstream pathway is not involved [67].
DEH is a developmental disorder with cartilaginous over-
growth of a portion of one or more epiphyses [68]. It pre-
dominantly affects the lower extremity on one side of the
body. It is usually restricted to either the medial (most fre-
quent) or lateral side of the limb (hemimelic). Similar to
osteochondroma, DEH is usually diagnosed prior to the
age of 15 years, more often in boys than in girls, and
growth of these lesions end at puberty as the growth plates
close [68,69]. In contrast to MO, malignant transforma-
tion has not been reported so far [68] and there does not
appear to be any genetic transmission [69-71].
MC is a rare disorder exhibiting, synchronous, both mul-
tiple osteochondromas and enchondromas in children. It
has an autosomal dominant mode of inheritance [72-74]
but the disorder has not been mapped in the human
genome so far. MC related osteochondromas characteris-
tically occur in the hands and feet, predominantly the dig-
its and toes, and point toward the adjacent growth plate,
while in MO the osteochondromas are mainly located in
the long or other tubular bones and point away from the
epiphysis [72]. Differentiation from MO is of great clinical
significance because in patients with MC the lesions do
not result in shortening or deformity of affected bones as
in MO, and may spontaneously decrease in size or resolve
completely, both clinically and radiologically [72,74].
Moreover, MO should be distinguished from enchondro-
matosis (Ollier disease and Maffucci syndrome), in which
multiple cartilage tumours are found in the medulla of
bone, with a predilection for the short tubular bones and
a unilateral predominance [75].
Growth plate signaling in the normal growth plate Figure 3
Growth plate signaling in the normal growth plate. 
Indian Hedgehog protein (IHh) is expressed in the prehyper-
trophic cells, and diffuses over a variable distance to its 
receptor Patched (PTCH). Subsequently, increased secretion 
of ParaThyroid Hormone Like Hormone (PTHLH) is induced 
at the apical perichondrium via an incompletely understood 
mechanism. PTHLH then diffuses to its receptor, whose 
expression is restricted to the late proliferating chondro-
cytes, inhibiting their further differentiation, resulting in less 
IHh producing cells, which closes the feedback loop. Thus, 
PTHLH regulates the pace of chondrocyte differentiation by 
delaying the progression of chondrocytes towards the hyper-
trophic zone, allowing longitudinal bone growth. Defective 
or absent EXT proteins leading to altered or absent HSPG 
expression at the cell surface may affect this negative feed-
back loop by disturbing the diffusion of IHh, produced at the 
pre-hypertrophic chondrocytes, towards its receptor Ptc.Orphanet Journal of Rare Diseases 2008, 3:3 http://www.ojrd.com/content/3/1/3
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Upon histopathological examination of osteochondroma
after surgical removal malignancy should be considered.
Malignant transformation in the cartilage cap of osteo-
chondroma leads to a secondary peripheral chondrosar-
coma. Occasionally, osteosarcomas and spindle cell
sarcomas develop in the stalk of the osteochondroma
[15,76-80]. Extremely rare is the occurrence of dedifferen-
tiated peripheral chondrosarcoma, in which a low-grade
chondrosarcoma that developed within an osteochon-
droma "dedifferentiates" into a high grade sarcoma
[81,82].
Genetic counselling
MO is an autosomal dominant disorder. Affected individ-
uals have 50% risk of transmitting the disorder to their
offspring. MO has nearly 100% penetrance. If the exact
mutation is known antenatal diagnosis is technically pos-
sible.
Management including treatment
Osteochondromas are only removed when they cause
pain, when they give functional complaints for instance
due to compression on nerves or vessels, or for cosmetic
reasons.
Surgical treatment of forearm deformities remains contro-
versial. In a retrospective series 23 MO patients corrective
osteotomy and/or lengthening of forearm bones was not
beneficial [83]. Moreover, one should consider the possi-
ble recurrence of ulnar shortening within 1.5 years when
operating skeletally immature patients [83,84]. The most
beneficial procedure was excision of the osteochondro-
mas. The simple removal of an osteochondroma can
improve forearm rotation and correct deformity [83],
especially if there is an isolated tumour of the distal part
of the ulna.
If the diagnosis of MO is established and all tumours are
identified, patients should be well instructed to seek ear-
lier medical attention if their condition changes, for
instance if there is pain or growth of a known lesion [61].
It is important to realise that no new osteochondromas
develop after puberty. Moreover, regular follow-up to dis-
cover potential malignant transformation at an early stage
to enable adequate treatment should be considered. The
risk of malignant transformation of osteochondroma
towards secondary peripheral chondrosarcoma is esti-
mated at 1–5% [2,4,5,13,14,34]. After skeletal maturation
a base-line bone scan is recommended [61]. Furthermore,
baseline plain radiographs of areas that can not be manu-
ally examined, like the chest, pelvis and scapula can be
performed [61]. After the base-line documentation one
should consider screening patients regularly, for instance
every year or every other year. There are as yet no studies
available that have proven efficacy of screening. If lesions
change over time, further examination, using magnetic
resonance (MR) imaging including contrast enhanced MR
sequences, is indicated [61].
In case of malignancy, en-bloc resection of the lesion and
its pseudocapsule with tumour-free margins, preferably in
a bone tumour referral centre, should be performed,
resulting in excellent long term clinical and local results.
The most common location is however the pelvis where
the large cartilage cap can be difficult to excise. In a series
of 61 patients with grade I or II secondary peripheral
chondrosarcoma of the pelvis published by Donati et al.,
a 3% local recurrence rate was found after wide resection,
in contrast with 23% after inadequate excision [85].
Prognosis
Osteochondromas are benign lesions and do not affect
life expectancy. The risk of malignant transformation is
1–5%. The prognosis for secondary peripheral chondrosa-
rcoma is depending on histological grade: 10 year survival
rates are 83% for grade I chondrosarcomas compared to
29% for grade III chondrosarcomas [86].
Unresolved questions
￿ How can the enormous difference in disease severity
within and between families be explained?
￿ What drives malignant transformation of osteochon-
droma and can this be prevented?
￿ What is the role of EXT in normal cartilage growth and
differentiation and in osteochondroma formation?
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